comparemela.com

Latest Breaking News On - மைக்கேல் லகார்ட் - Page 4 : comparemela.com

Centre Presse : Promenade bucolique à La Vallée des arbres

Centre Presse : Promenade bucolique à La Vallée des arbres
centre-presse.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from centre-presse.fr Daily Mail and Mail on Sunday newspapers.

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business From Novasep

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business From Novasep
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.

Belgium: Thermo Fisher acquires Henogen for €725m

LaingBuisson News Thermo Fisher Scientific, the world’s largest maker of scientific instruments, is to acquire Belgian viral vector manufacturing business Henogen for €725m (US$880.3m) in cash. A subsidiary of Groupe Novasep, Henogen provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers from two locations in Seneffe and Gosselies. Founded more than… You must be a HMI Subscriber to view this content. Adrian Murdoch has more than 25 years’ experience as an international journalist. He started his career at World Link, the magazine of the World Economic Forum. He covered debt capital markets for Reuters in Singapore throughout the Asian Financial Crisis, and then the European Central Bank in Frankfurt. Most recently he covered healthcare markets in Southeast Asia and worldwide. As a freelancer he has worked for Forbes, The Wall Street Journal, Euromoney, the Scotsman and the BBC. The author of a

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Jan 21 2021 Read 877 Times Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash. Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.